NCT07092566RecruitingPhase 3
R.E.C.K vs Exparel in Robotic Nephrectomy
Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- First submitted
- 21 Jul 2025
- Start date
- 14 Nov 2025
- Primary completion date
- Oct 2027
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Kidney cancer
- NCT number
- NCT07092566
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 170
- From 14 Nov 2025 to the primary completion date, Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic opioid use within 30 days (as per patient report) prior to randomization (defined as ≥ 30 MME/day)
Other illness
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
- Known allergy to R.E.C.K. and/or Exparel
Other
- Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling investigator
- Known pregnancy
Who the study is looking for
- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥ 18 years at the time of consent.
- Planned robotic partial or radical nephrectomy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Levine Cancer Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.